Pharvaris (PHVS) Other Gross PP&E Adjustments (2025 - 2026)
Pharvaris posted quarterly Other Gross PP&E Adjustments of -$83056.2 for Q1 2026, up 37.67% on a QoQ basis from -$133260.9 in Q4 2025.
Pharvaris (PHVS) has 2 years of Other Gross PP&E Adjustments data on file, last reported at -$83056.2 in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments changed N/A year-over-year to -$83056.2; the trailing twelve-month figure through Mar 2026 stood at -$83056.2 (changed N/A YoY), and the FY2025 full-year result was -$129341.9, changed N/A from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$83056.2, up from -$133260.9 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$83056.2 in Q1 2026 and bottomed at -$133260.9 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | -83,056.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83,056.21 |
| Mar 31, 2026 | -83,056.21 |
| Dec 31, 2025 | -133,260.87 |
| Dec 31, 2025 | -133,260.87 |